Haoxi Health Technology Ltd trading halted, news pending
Trading Halt: Haoxi Health Technology (HAO) Ltd has had its trading halted due to pending news.
Recent Developments: The company recently announced a 1-for-25 reverse share split and approved key resolutions at their 2025 Annual General Meeting, among other strategic initiatives.
Trade with 70% Backtested Accuracy
Analyst Views on HAO
About HAO
About the author

- Reverse Stock Split: Haoxi Health Technology announced a reverse stock split of its Class A and Class B ordinary shares at a ratio of 1-for-128, reducing the outstanding Class A shares from 235,504,007 to approximately 1,839,876 and Class B shares from 690,800 to about 5,397, which may impact shareholder equity and market liquidity.
- Trading Schedule: The reverse stock split will take effect on May 21, 2026, with Class A shares trading on Nasdaq on an adjusted basis, aimed at increasing stock price; however, the company cannot guarantee that post-split prices will remain above pre-split levels, introducing uncertainty for investors.
- Shareholder Guidance: Shareholders holding shares in book-entry form need not take action, as Transhare Corporation LLC will act as the exchange and paying agent, facilitating the stock conversion process and minimizing operational complexities associated with the split.
- Company Overview: Haoxi Health Technology, based in Beijing, specializes in providing online marketing solutions for the healthcare sector, focusing on reducing costs and increasing efficiency through one-stop solutions like short video marketing, thereby strengthening its competitive position in the Chinese market as demand for healthcare advertising rises.
- Funding Size: Haoxi Health Technology successfully closed a $6.5 million registered direct offering through Univest Securities, selling 9 million Class A ordinary shares and 16,999,998 pre-funded warrants, indicating strong demand for its online marketing solutions in the healthcare sector.
- Equity Structure: The offering priced shares at $0.25 each, with pre-funded warrants exercisable at $0.0026, reflecting investor confidence in the company's growth potential, which may enhance shareholder value.
- Market Positioning: Haoxi focuses on short-form video and news feed advertising, leveraging the rapid growth of major Chinese digital platforms to provide one-stop online marketing solutions for healthcare clients, further solidifying its market leadership.
- Strategic Partnership: Univest Securities acted as the sole placement agent, showcasing its influence in the capital markets and assisting Haoxi Health Technology in securing funding to drive business expansion and technological innovation.
- Strategic Cooperation Agreement: Haoxi Health and Eaglepoint AI have signed a three-year strategic cooperation agreement, committing joint R&D, data, and channel resources to launch an AI health management platform, marking Haoxi's exploration of new opportunities in the AI healthcare sector.
- Innovative Technology Application: This collaboration represents the first deployment of Eaglepoint AI's Aquila data engine and multimodal model evaluation system in a health management scenario, expected to enhance the intelligence of health management and drive the development of preventive healthcare applications.
- Market Promotion Support: Haoxi Health plans to leverage its extensive marketing networks to provide user reach and commercial conversion support, while Eaglepoint AI will handle technical support, including model training and data security compliance, ensuring smooth project execution.
- Phase One Objectives: The initial phase will launch the

Haoxi Health Technology's Financial Performance: The company has a low return on capital employed (ROCE) of 4.1%, significantly below the media industry average of 9.5%, indicating underperformance despite an increase in capital employed and revenue.
Growth Strategy and Risks: Although Haoxi is reinvesting for growth, leading to higher sales, its stock has plummeted 82% over the past year, suggesting potential underlying issues, including five warning signs that investors should be aware of.

Oxford Industries Earnings Report: Oxford Industries, Inc. shares rose 15.1% in pre-market trading after reporting Q2 earnings of $1.26 per share, exceeding analyst expectations of $1.18, and raising its FY25 EPS guidance despite a revenue miss.
Pre-Market Stock Movements: Several stocks saw significant pre-market trading movements, with YY Group Holding Limited gaining 122.9% and Vince Holding Corp rising 101%, while Robin Energy Ltd. and TOP Financial Group Limited experienced declines of 23.5% and 21.6%, respectively.
MongoDB's Strong Performance: MongoDB, Inc. shares surged 31% in pre-market trading after reporting better-than-expected second-quarter results and raising its fiscal 2026 adjusted EPS guidance to between $3.64 and $3.73.
Other Gainers: Notable pre-market gainers included NovaBay Pharmaceuticals (up 66.7% due to a special cash dividend), Bollinger Innovations (up 32.1%), and BioXcel Therapeutics (up 19.5% after announcing Phase 3 data).
Pre-Market Losers: Stocks that declined in pre-market trading included Fenbo Holdings (down 16.8%), SCWorx Corp (down 15.2%), and Beneficient (down 14.3%).
Market Overview: The article provides a snapshot of various stocks' performances in pre-market trading, highlighting significant movements both upward and downward.








